Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of BGB-290 With Temozolomide in Recurrent Gliomas With IDH1/2 Mutations

NCT03914742 is registered in ClinicalTrials.gov with Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as lead sponsor.

NCT NCT03914742
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03914742 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of BGB-290 With Temozolomide in Recurrent Gliomas With IDH1/2 Mutations
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase
Phase 1/2
Overall status
Completed
Start date
February 16, 2020
Completion date
October 31, 2023
Enrollment
67 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

idh1 mutation, idh2 mutation, recurrent glioblastoma, recurrent who grade ii glioma, recurrent who grade iii glioma